KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Operating Expenses (2016 - 2025)

Vertex Pharmaceuticals has reported Operating Expenses over the past 17 years, most recently at $2.0 billion for Q4 2025.

  • Quarterly results put Operating Expenses at $2.0 billion for Q4 2025, up 5.2% from a year ago — trailing twelve months through Dec 2025 was $7.8 billion (down 30.44% YoY), and the annual figure for FY2025 was $7.8 billion, down 30.44%.
  • Operating Expenses for Q4 2025 was $2.0 billion at Vertex Pharmaceuticals, up from $1.9 billion in the prior quarter.
  • Over the last five years, Operating Expenses for VRTX hit a ceiling of $6.2 billion in Q2 2024 and a floor of $836.5 million in Q1 2021.
  • Median Operating Expenses over the past 5 years was $1.5 billion (2023), compared with a mean of $1.7 billion.
  • Biggest five-year swings in Operating Expenses: surged 319.98% in 2024 and later tumbled 70.56% in 2025.
  • Vertex Pharmaceuticals' Operating Expenses stood at $1.2 billion in 2021, then increased by 6.22% to $1.3 billion in 2022, then grew by 20.49% to $1.5 billion in 2023, then rose by 23.33% to $1.9 billion in 2024, then increased by 5.2% to $2.0 billion in 2025.
  • The last three reported values for Operating Expenses were $2.0 billion (Q4 2025), $1.9 billion (Q3 2025), and $1.8 billion (Q2 2025) per Business Quant data.